Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

beta-Thalassemia 1Supratentorial Brain Tumor Surgery 1Post-operative Residual Curarization 1Neoplasms 1Hepatoblastoma 1Brain Neoplasms 1

Interventions

sintilimab 1pembrolizumab 1lenvatinib 1camrelizumab 1Sugammadex 1Neoadjuvant Therapy 1Irinotecan 1Immune Checkpoint Inhibitors 1Granulocyte-Macrophage Colony-Stimulating Factor 1Granulocyte Colony-Stimulating Factor 1Drug Therapy 1Doxorubicin 1Cyclophosphamide 1Cisplatin 1Chemotherapy, Adjuvant 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Hepatoblastoma × Sugammadex × Clear all
NCT03728543 2018-11-02

the Efficacy and Safety of Sugammadex in Children 0-2 Years Old

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Phase 2/3 Unknown
62 enrolled
Gastrointestinal

Neoplasms, beta-Thalassemia, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡